Clinical Trial

A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men and Women

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Part A: The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3031185 in healthy male subjects following administration of multiple rising doses. Part B: The main objectives of Part B of this trial are to investigate safety, tolerability, and pharmacokinetics (PK) of BI 3031185 in healthy male subjects and female subjects of non-childbearing potential following oral administration of multiple doses of BI 3031185.
Protocol Amendment History 2 changes
notable Enrollment increased: 60 -> 100 participants 2026-05-23
minor Trial arms changed: 6 -> 7 2026-05-23
Trial Details
NCT Number NCT06916702
Lead Sponsor Boehringer Ingelheim
Conditions Healthy
Enrollment 100 participants
Start Date 2025-04-07
Primary Completion 2026-10-07 (estimated)
Study Completion 2026-10-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-22